Adrenomed’s goal is to fill the gap in patient treatment further downstream of inflammation with Adrecizumab, the first sepsis therapy candidate to target an important causal pathophysiology of ...

Advances in the understanding of the pathophysiology of sepsis have occurred in the last decade. Previously, sepsis was viewed primarily as an inflammatory disorder. More recent studies indicate ...